Literature DB >> 8840221

Interleukin-10 (IL-10) secretion in systemic lupus erythematosus and rheumatoid arthritis: IL-10-dependent CD4+CD45RO+ T cell-B cell antibody synthesis.

M al-Janadi1, A al-Dalaan, S al-Balla, M al-Humaidi, S Raziuddin.   

Abstract

Interleukin-10 (IL-10) is a major immunoregulatory cytokine and has a multitude of immunomodulatory effects in the immune system. In this study, we have examined the secretion and in vitro function of IL-10 in B cell hyperactivity in antibody production in two common autoimmune diseases, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). IL-10 was detectable in serum of all active SLE and serum and synovial fluid samples of all RA patients but in none of the normal controls. B cells and CD4+CD45RO+ "memory" T cells secreted highly enhanced levels of IL-10 in SLE and RA versus normals. Increased IgM and IgG production by B cells-CD4+CD45RO+ T cells in SLE and RA was IL-10 dependent, since neutralization of IL-10 cytokine by anti-IL-10 antibody drastically reduced Ig synthesis in these coculture experiments. B cell hyperactivity in autoantibody production in SLE and RA may be a function of IL-10-dependent CD4+CD45RO+ Th2 cell activation. Therefore, IL-10 may play an important role in highly disturbed immune system and B cell-T cell function in these immune disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8840221     DOI: 10.1007/bf01541225

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  38 in total

Review 1.  Biological properties of interleukin 10.

Authors:  M Howard; A O'Garra; H Ishida; R de Waal Malefyt; J de Vries
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

2.  Increased frequency of V beta 17-positive T cells in patients with rheumatoid arthritis.

Authors:  G Zagon; J R Tumang; Y Li; S M Friedman; M K Crow
Journal:  Arthritis Rheum       Date:  1994-10

3.  Hyperreactivity of activated B cells to B cell growth factor in patients with systemic lupus erythematosus.

Authors:  Y Ueda; T Sakane; T Tsunematsu
Journal:  J Immunol       Date:  1989-12-15       Impact factor: 5.422

4.  In vivo production of interleukin-10 by malignant cells in AIDS lymphomas.

Authors:  D Emilie; R Touitou; M Raphael; M Peuchmaur; O Devergnee; D Rea; J Coumbraras; M C Crevon; L Edelman; I Joab
Journal:  Eur J Immunol       Date:  1992-11       Impact factor: 5.532

5.  IL-10 mediates susceptibility to Trypanosoma cruzi infection.

Authors:  S G Reed; C E Brownell; D M Russo; J S Silva; K H Grabstein; P J Morrissey
Journal:  J Immunol       Date:  1994-10-01       Impact factor: 5.422

6.  Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10.

Authors:  R A Baiocchi; M E Ross; J C Tan; C C Chou; L Sullivan; S Haldar; M Monne; M V Seiden; S K Narula; J Sklar
Journal:  Blood       Date:  1995-02-15       Impact factor: 22.113

7.  Cytokine gene profile in circulating blood mononuclear cells from patients with systemic lupus erythematosus: increased interleukin-2 but not interleukin-4 mRNA.

Authors:  D A Horwitz; H Wang; J D Gray
Journal:  Lupus       Date:  1994-10       Impact factor: 2.911

8.  IL-10 enhances expression of the IL-2 receptor alpha chain on T cells.

Authors:  S B Cohen; P D Katsikis; M Feldmann; M Londei
Journal:  Immunology       Date:  1994-11       Impact factor: 7.397

9.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

10.  Interleukin 10: a novel stimulatory factor for mast cells and their progenitors.

Authors:  L Thompson-Snipes; V Dhar; M W Bond; T R Mosmann; K W Moore; D M Rennick
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

View more
  15 in total

Review 1.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

Review 2.  New therapies in development for autoimmune diseases: their rationale for combination treatment.

Authors:  V Strand
Journal:  Springer Semin Immunopathol       Date:  2001

3.  The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus.

Authors:  J Tyrrell-Price; P M Lydyard; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

4.  Immune complexes from SLE sera induce IL10 production from normal peripheral blood mononuclear cells by an FcgammaRII dependent mechanism: implications for a possible vicious cycle maintaining B cell hyperactivity in SLE.

Authors:  J Rönnelid; A Tejde; L Mathsson; K Nilsson-Ekdahl; B Nilsson
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

5.  Monocytes differentiated with GM-CSF and IL-15 initiate Th17 and Th1 responses that are contact-dependent and mediated by IL-15.

Authors:  Kristina M Harris
Journal:  J Leukoc Biol       Date:  2011-07-01       Impact factor: 4.962

6.  Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG).

Authors:  Y M Huang; P Kivisäkk; V Ozenci; R Pirskanen; H Link
Journal:  Clin Exp Immunol       Date:  1999-11       Impact factor: 4.330

7.  Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies.

Authors:  L Mathsson; E Ahlin; C Sjöwall; T Skogh; J Rönnelid
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

Review 8.  The dual nature of interleukin-10 in pemphigus vulgaris.

Authors:  Michael Jeffrey Cho; Christoph T Ellebrecht; Aimee S Payne
Journal:  Cytokine       Date:  2014-11-22       Impact factor: 3.861

Review 9.  Interleukin-10 paradox: A potent immunoregulatory cytokine that has been difficult to harness for immunotherapy.

Authors:  Ankit Saxena; Sam Khosraviani; Sanjeev Noel; Divya Mohan; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cytokine       Date:  2014-12-04       Impact factor: 3.861

10.  Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE.

Authors:  Vilma Urbonaviciute; Barbara G Fürnrohr; Silke Meister; Luis Munoz; Petra Heyder; Francesco De Marchis; Marco E Bianchi; Carsten Kirschning; Hermann Wagner; Angelo A Manfredi; Joachim R Kalden; Georg Schett; Patrizia Rovere-Querini; Martin Herrmann; Reinhard E Voll
Journal:  J Exp Med       Date:  2008-12-08       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.